Noxopharm Ltd
ASX:NOX

Watchlist Manager
Noxopharm Ltd Logo
Noxopharm Ltd
ASX:NOX
Watchlist
Price: 0.096 AUD 2.13% Market Closed
Market Cap: 28.1m AUD

Noxopharm Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Noxopharm Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Noxopharm Ltd
ASX:NOX
EPS (Diluted)
AU$0
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
EPS (Diluted)
$0
CAGR 3-Years
17%
CAGR 5-Years
-27%
CAGR 10-Years
-10%
Mesoblast Ltd
ASX:MSB
EPS (Diluted)
$0
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
12%
CSL Ltd
ASX:CSL
EPS (Diluted)
$6
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
8%
Telix Pharmaceuticals Ltd
ASX:TLX
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
EPS (Diluted)
AU$0
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Noxopharm Ltd
Glance View

Market Cap
28.1m AUD
Industry
Biotechnology

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).

NOX Intrinsic Value
0.073 AUD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Noxopharm Ltd's EPS (Diluted)?
EPS (Diluted)
-0 AUD

Based on the financial report for Jun 30, 2025, Noxopharm Ltd's EPS (Diluted) amounts to -0 AUD.

What is Noxopharm Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
31%

Over the last year, the EPS (Diluted) growth was -100%. The average annual EPS (Diluted) growth rates for Noxopharm Ltd have been 31% over the past three years .

Back to Top